IP Library Granted Patent US 10,231,960
Granted Patent B2
US 10,231,960 · App. 15/249,088 · Granted Mar 19, 2019

Methylphenidate-prodrugs, processes of making and using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,231,960
App. No.
15/249,088
Granted
Mar 19, 2019
Kind
B2
Abstract

The present technology is directed to prodrugs and compositions for the treatment of various diseases and/or disorders comprising methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof. In some embodiments, the conjugates further include at least one linker. The present technology also relates to the synthesis of methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof or combinations thereof.

Claims (5)

1. A composition comprising at least one conjugate of methylphenidate having a structure selected from the group consisting of

2. The composition of claim 1 , wherein the composition is in a form of a gel, a polymorph, a tablet, a capsule, a caplet, a troche, a lozenge, an oral powder, a solution, a thin strip, an oral thin film (OTF), an oral strip, a rectal film, a transdermal patch, a syrup, a suspension, an inhalation compound, or a suppository.

3. The composition of claim 1 for use in a method of treating a patient having a disease, disorder or condition selected from the group consisting of attention-deficit hyperactivity disorder, attention deficit disorder, autistic spectrum disorder, autism, Asperger's disorder, pervasive developmental disorder, sleep disorder, obesity, depression, bipolar disorder, eating disorder, chronic fatigue syndrome, schizophrenia, major depressive disorder, narcolepsy, postural orthostatic tachycardia syndrome, lethargy, and neural insult comprising orally administering to the patient a pharmaceutically effective amount of the composition.

4. The composition of claim 1 , wherein the composition is a prodrug.

5. A compound having a structure selected from the group consisting of

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2026
From: ZEVRA THERAPEUTICS, INC.
To: COMMAVE THERAPEUTICS SA
Reel/Frame 074194/0909 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2026
From: ZEVRA THERAPEUTICS, INC.
To: COMMAVE THERAPEUTICS SA
Reel/Frame 074186/0531 →
RELEASE OF SECURITY INTEREST Recorded Mar 13, 2026
From: ALTER DOMUS (US) LLC
To: ZEVRA THERAPEUTICS, INC.
Reel/Frame 075080/0907 →
SECURITY INTEREST Recorded Apr 8, 2024
From: ZEVRA THERAPEUTICS, INC.
To: ALTER DOMUS (US) LLC
Reel/Frame 067040/0637 →
CHANGE OF NAME Recorded Feb 26, 2024
From: KEMPHARM, INC.
To: ZEVRA THERAPEUTICS, INC.
Reel/Frame 066679/0668 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S ADDRESS ON THE ASSIGNMENT DOCUMENT PREVIOUSLY RECORDED AT REEL: 040312 FRAME: 0818. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Oct 19, 2021
From: GUENTHER, SVEN; CHI, GUOCHEN; BERA, BINDU; MICKLE, TRAVIS; BERA, SANJIB
To: KEMPHARM, INC.
Reel/Frame 057848/0159 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S ADDRESS PREVIOUSLY RECORDED AT REEL: 040312 FRAME: 0818. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 5, 2018
From: GUENTHER, SVEN; CHI, GUOCHEN; BERA, BINDU; MICKLE, TRAVIS; BERA, SANJIB
To: KEMPHARM, INC.
Reel/Frame 047320/0697 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2016
From: GUENTHER, SVEN; MICKLE, TRAVIS; CHI, GUOCHEN; BERA, BINDU; BERA, SANJIB
To: KEMPHARM, INC.
Reel/Frame 040312/0818 →